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in CR1 achieved sustained remissions using autoSCT. Of
those who relapse, nearly 50% proceed to alloSCT and 31%
are long-term disease-free survivors. Relapse-free survival
has likely decreased in the most recent era due to changes
in patient selection. AutoSCT remains a reasonable option
for int-risk patients with AML in CR1, with outcomes
rivaling those currently achieved with alternative donor
alloSCT.163
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Background: High dose chemotherapy (HDC) followed by
autologous stem cell transplant (ASCT) is considered the
standard of care for patients with multiple myeloma (MM).
With most patients receiving induction therapy that in-
cludes corticosteroids. The combined effect of prior ther-
apy for myeloma and ASCT related complications may
result in hypotension and require intensive medical
treatment. To date the incidence of adrenal insufﬁciency in
the setting of ASCT is unknown. The effects of this under-
lying disorder in regards to post transplant outcome
remain unknown as well. We set out to compare the out-
comes of patients with multiple myeloma who underwent
ASCT with adrenal insufﬁciency compared to those with
sufﬁcient adrenal function.
Methods: This was a prospective study in 13 consecutive
patients with MM admitted for HDC and ASCT at Henry Ford
Hospital between February 2014 through June 2014, with
the ﬁrst patient sample being obtained in on 2/14/2014 and
last sample recorded in 6/23/2014. Random cortisol levels
were obtained on the day of admission or day -2 (Figure 1),
prior to the start of HDC. All prior therapies included
corticosteroids and consisted of the following RVD, DCEP,
RD, VD, DT-PACE. Patients were classiﬁed into twoFigure 1groups those with cortisol levels > 5 and those patients
who had cortisol levels <5. Endpoints analyzed included
hypotension, septic shock, and duration of antibiotic
therapy.
Results: Of the 13 patients analyzed the median age was 60
years old (range 53-78), gender 8 male patients 5 female.
All patients underwent HDC with Melphalan and ASCT. Of
the 13 patients in which data was obtained 3/13 23% had
adrenal insufﬁciency prior to high dose Melphalan and
ASCT. With a median cortisol level of 3.2 in the patient
cohort who were found to be adrenal insufﬁcient. The
incidence of hypotension was 2/3 66% in the adrenal
insufﬁcient patients compared 1/10 10% in the cohort with
sufﬁcient adrenal function. Septic shock occurred in 2/3
66% of the adrenal insufﬁcient compared to 0/10 in the
adrenal sufﬁcient group. The median duration of antibiotic
therapy was 5 days in the adrenal insufﬁcient cohort
compared to 2 days in the patients with adequate adrenal
function.
Conclusion: In this small cohort of consecutive patients from
a single center, we found that there was a high incidence of
adrenal insufﬁciency 23% in patients undergoing ASCT. The
treatment regimens varied in the study group with all pa-
tients receiving corticosteroid therapy in their induction
regimen. Given the unexpectedly high incidence of adrenal
insufﬁciency a consideration should be given to check a
random cortisol level prior to the initiation of HDC. Supple-
mental therapy or treatment should be considered in this
high risk group to avoid unnecessary complications and
prolonged antibiotic use and supportive care in this patient
cohort.
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Background: SCIAR are often seen during transplants, but
enough data are not available. In the past SCIAR were
attributed to adverse event (AE) from DMSO..
